Eucrates Biomedical Acquisition Corp.

Overview

• IndustryBlank Checks¹
• HeadquartersNew York, New York¹
• Incorporated inVirgin Islands, British²
• Business address250 West 55Th Street, Suite 13D, New York, Ny 10019²
• Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company²

See how the biggest companies compare on our leaderboards

Corporate structure

Eucrates Biomedical Acquisition Corp. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

Leadership

Who has led Eucrates Biomedical Acquisition Corp., and when. Pick a name to see everywhere that person has worked.

• Chief executive officerParag Saxena Oct 23, 2020 to Nov 27, 2020⁷
• PresidentEvangelos Vergetis Oct 23, 2020 to Oct 23, 2020⁸
• Chief financial officerGonzalo Cordova Oct 23, 2020 to Oct 23, 2020⁹
• Chief operating officerEvangelos Vergetis Oct 23, 2020 to Oct 23, 2020⁸

Timeline

1. Apr 11, 20238-K Other events¹⁵
2. Apr 3, 20238-K New debt or obligation¹⁶
3. Feb 16, 20238-K Entered a material agreement; New debt or obligation; Unregistered sale of shares¹⁷
4. Nov 8, 20228-K New debt or obligation¹⁸
5. Oct 31, 20228-K Bylaws or fiscal year changed¹⁹
6. Oct 24, 20228-K Shareholder vote; Regulation FD disclosure²⁰
7. Jan 26, 20228-K Entered a material agreement; New debt or obligation; Unregistered sale of shares²¹
8. Nov 19, 20218-K Earlier financial statements no longer reliable²²
9. Oct 23, 2020New chief executive Parag Saxena becomes CEO⁷

Filings

28 filings to the SEC since October 2021: 3 annual reports, 4 quarterly reports, 8 major events, 2 large holders, 11 other. The latest 20:

1. May 8, 202315-12G EDGAR
2. Apr 13, 202310-K EDGAR
3. Apr 11, 20238-K EDGAR
4. Apr 3, 20238-K EDGAR
5. Mar 29, 2023NT 10-K EDGAR
6. Feb 16, 20238-K EDGAR
7. Feb 10, 2023SC 13G/A EDGAR
8. Nov 14, 202210-Q EDGAR
9. Nov 8, 20228-K EDGAR
10. Oct 31, 20228-K EDGAR
11. Oct 24, 20228-K EDGAR
12. Oct 12, 2022DEF 14A EDGAR
13. Oct 12, 2022UPLOAD EDGAR
14. Oct 5, 2022CORRESP EDGAR
15. Oct 5, 2022PRER14A EDGAR
16. Oct 4, 2022UPLOAD EDGAR
17. Sep 28, 2022PRE 14A EDGAR
18. Aug 15, 202210-Q EDGAR
19. May 23, 202210-Q EDGAR
20. May 16, 2022NT 10-Q EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• James E. FlynnSC 13G/A, 1 filing Feb 10, 2023²³
• PRICE T ROWE ASSOCIATES INC /MD/SC 13G, 1 filing Feb 14, 2022²⁴

SEC filer profile

How Eucrates Biomedical Acquisition Corp. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGAREucrates Biomedical Acquisition Corp.¹
• CIK0001822929
• Filer statusNon-accelerated filer<br>smaller reporting company<br>emerging growth company¹
• Incorporated inVirgin Islands, British¹
• Fiscal year endsDecember 31¹
• Industry code (SIC)6770 Blank Checks¹
• Business address250 West 55Th Street, Suite 13D, New York, NY 10019¹
• Phone(212) 710-5220¹
• Shares outstanding4,206,059 as of Apr 13, 2023³
• Public float$106.8M as of Jun 30, 2022³
• On EDGAR sinceSep 2, 2020¹
• Filings74 in all: 8-K (14), 3 (11), 10-Q (7), CORRESP (5), SC 13G (5), UPLOAD (4), 10-K (3), 4 (3)¹
  All 24 form types

  NT 10-Q (3), 10-K/A (2), NT 10-K (2), S-1/A (2), SC 13G/A (2), 15-12G (1), 25-NSE (1), 424B4 (1), 8-A12B (1), CERT (1), DEF 14A (1), DRS (1), EFFECT (1), PRE 14A (1), PRER14A (1), S-1 (1)

• Latest filingsAnnual report (10-K) Apr 13, 2023
  Quarterly report (10-Q) Nov 14, 2022
  Proxy statement (DEF 14A) Oct 12, 2022
  Latest 8-K (8-K) Apr 11, 2023